Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodegenerative disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback